Exact Sciences Corp EXAS
Revenue Intelligence Report • 59 quarters of SEC filing data • Updated 2026-03-15
Latest quarterly revenue is $878 million, supported by a dataset spanning 59 quarters. In the model, SG&A spending yields a positive long-run revenue impact of $1.42 per $1 spent, while R&D spending yields a negative long-run impact of $-3.71 per $1 spent, indicating SG&A efficiency as the primary long-run driver of revenue. A holdout test shows the model predicting $0.9B against actual $0.9B, a 3.0% error, offering credibility for near-term projections. The FY revenue forecast is $3.8B, up 17.1% year over year, signaling solid top-line growth even as ROI dynamics emphasize SG&A investments over R&D.
Investment Thesis
At 2884.2% MAPE, the model captures Exact Sciences Corp's broad revenue trajectory, though quarterly variability suggests sensitivity to external factors. Each $1 of SG&A spending generates $1.42 in revenue, reflecting strong commercial efficiency.
Revenue Forecast
Quarterly Detail
| Quarter | Model Forecast | Actual | 95% Range | YoY Growth | Status |
|---|---|---|---|---|---|
| Q4 2025 | $0.9B | $0.9B | $0.8B – $0.9B | +19.5% | ✓ In range |
| Q2 2026 | $0.9B | $0.8B – $0.9B | +25.9% | ||
| Q3 2026 | $0.9B | $0.9B – $1.0B | +16.7% | ||
| Q4 2026 | $1.0B | $0.9B – $1.0B | +13.0% | ||
| Q1 2027 | $1.0B | $0.9B – $1.1B | +14.5% |
How Spending Drives Revenue
Want this analysis for your portfolio?
I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.
Get in Touch